Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech Limited LSE:HCM London Ordinary Share KYG4672N1016 ORD USD1
  Price Change % Change Share Price Shares Traded Last Trade
  -120.00p -2.76% 4,220.00p 1,493 08:00:00
Bid Price Offer Price High Price Low Price Open Price
4,140.00p 4,300.00p 4,220.00p 4,220.00p 4,220.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 167.90 -67.95 -88.61 2,807.7

Hutchison China Meditech (HCM) Latest News

More Hutchison China Meditech News
Hutchison China Meditech Takeover Rumours

Hutchison China Meditech (HCM) Share Charts

1 Year Hutchison China Meditech Chart

1 Year Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Hutchison China Meditech (HCM) Discussions and Chat

Hutchison China Meditech Forums and Chat

Date Time Title Posts
22/5/201907:45(Chi-Med)Hutchinson China Meditech Limited1,930
31/7/201807:25Hutchison Chi-Med (HCM) One to Watch 1
23/7/201810:55Hutchison Chi-Med (HCM) One to Watch on Monday 1
13/6/201707:54Hutchison China Meditech- CHARTS AND DISCUSSION74

Add a New Thread

Hutchison China Meditech (HCM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
13:57:434,229.60251,057.40O
13:18:404,184.0038816,233.92O
13:16:084,184.001275,313.68O
13:15:424,184.0015627.60O
12:57:224,184.0024610,292.64O
View all Hutchison China Meditech trades in real-time

Hutchison China Meditech (HCM) Top Chat Posts

DateSubject
24/5/2019
09:20
Hutchison China Meditech Daily Update: Hutchison China Meditech Limited is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchison China Meditech was 4,340p.
Hutchison China Meditech Limited has a 4 week average price of 3,625p and a 12 week average price of 3,625p.
The 1 year high share price is 5,670p while the 1 year low share price is currently 3,185p.
There are currently 66,532,683 shares in issue and the average daily traded volume is 2,240 shares. The market capitalisation of Hutchison China Meditech Limited is £2,807,679,222.60.
06/5/2019
03:42
lauders: I see the newly adjusted share price will coincide with this HK event: Https://www.hkexgroup.com/Media-Centre/Corporate-Events/HKEX-Biotech-Summit/Programme?sc_lang=en Could be interesting? Or, I may be reading too much into it ;-)
25/4/2019
02:44
lauders: Will there be any detail on the AGM anywhere NofS? Would be nice to read more detailed thoughts/impressions post event :-) Personally I can see HCM's share price weakening until the shares are adjusted. Once that is over we may see them strengthen again. I could be totally wrong of course!
28/3/2019
07:53
waldron: https://uk.advfn.com/stock-market/london/hutchison-china-meditech-HCM/share-news/Hutchison-China-Meditech-Limited-Savolitinib-Lung/79568381
14/3/2019
22:03
dbadvn: Met Johnny Cheng and Mark Lee Wed am. Both very impressive and obviously on top of there game. Lauders - "I would be interested in knowing why HCM don't look to market more drugs within China from other global pharmaceutical companies" They acknowledged that they have done this in the past and say they would do so again if the commercial deal was correct , but they want to essentially focus on there own products. The large gap in cost between local and western drugs means that the market is limited even in China apparently. Also local companies are paying far too much for marketing rights for generics. Reading between the lines it would also seem that Western companies are building out their own sales groups as the Chinese Govt loosens requirements for partners/ JV etc. Sporti - "I wish to know if the company has any plans of expanding its commercial platform into the neighbouring countries and subsequently a Global pharma. " Yes is the short answer. In the very long term they are focused on becoming the first Chinese global Parma company. They will sell products into neighbouring countries via license agreements or agencies but are focusing first on China , USA and Europe. During this part of the discussion the relationship with Eli Lilley came up and it was obvious that this was the source of great frustration to them for the last 2 years or so - basically they stopped just short of saying that Lilley had tried to block their route to market . New arrangement is much improved although having Lilley sell in China and HCM sell outside China seems rather perverse....Upside is much better terms and, lower cost to HCM and compensation if Lilley try to launch competitive drug in China and increased royalities. Were disappointed that market did not recognise this but realised it was probably too technical . Unless I picked this up the wrong way this is the opposite of NoS and my previous understanding - I will follow up on that. At the end of the conversation they gave the distinct impression that they will avoid partnering within China if possible.... Other points: Dropped Epitinihib due to the success of Tagrissso but very excited by the Savo / Tagrisso combination ( Savannah ). Initial sales of Elunate going very well - past expectations. HMPL 689 showing increasing signs of being a success and has large market. Near term news flow WILL be good.... CFO discussed cash position - just will not be nailed down on cash flow positive expectations but admits cash is always on his mind. Don't expect to go to market for at least two years unless for a specific and exciting reason. Ready to outright sell an asset if they needed to and it was not core. 2nd land site sale will only come after next meeting of Chinese govt ( Q2) but value of land going up all the time . Not figured into forecasts because of uncertainty of timing. Also said change of Huchison management may mean that they will consider selling some equity to avoid consolidation accounting treatment which means Huchison books a loss. Saw this as a positive move for share price if it happens ( takeover premium ). Lots of the detail is in their presentation but overall a great meeting and gives me a lot of confidence
10/1/2019
15:46
robert longcroft: Haved followed Nerds of steel for some fair time now & appreciate his positive view on this company even when it has taken such a bashing. Bit concerned as to how low price will be driven before it bottoms out. I note the share price is just starting to wain again this afternoon. Rob longcroft
10/1/2019
14:56
lauders: See HCM are participating in this per their website: 18 Jan 2019 Bloomberg Intelligence - Harnessing China Biotech’s Potential Bloomberg Hong Kong Office Https://www.chi-med.com/investors/event-information/ Let's hope we start to climb back up share price wise soon!
13/12/2018
08:12
nhb001: Still at a £1+ discount to the US share price.
16/11/2018
11:08
lauders: Quite miti 1000! Whether you believe what the IC say or not here is their take on the news: IC TIP UPDATES: It’s been a morning of clinical trial failures across the pharmaceutical industry, but one of the biggest casualties is Hutchison China Meditech (HCM), which has revealed its final-phase trial of fruquintinib in China has failed to demonstrate “a statistically significant increase in overall survival” amongst advanced non-small cell lung cancer patients. This marked one of four important drug trials for Chi-Med, as it hopes to build on fruquintinib’s commercial launch (the drug has already been approved to treat advanced colorectal cancer). It’s a big disappointment - evident in the 15 per cent share price drop in early trading - but chairman Simon To says he still has long-term faith in the drug, as well as the other trials currently underway. We see this morning’s de-rating as a second buying opportunity. Also note the AZ news today and the IC's feedback on the same page. Https://www.investorschronicle.co.uk/shares/2018/11/16/news-tips-hutchison-china-meditech-imperial-brands-astrazeneca-more/
14/9/2018
20:55
sportii: Chi-med share price has not been moving in the positive direction, even after the major news of first drug approval. Due to the unfortunate geopolitical situation, institutional buyers in the USA are not showing any interest. Hence, share price is suffering and we, long time holders, are disappointed. Unless, there are new buyers who are willing to buy, share price will not move up. That will be the case even if the company gets approval for two or more drug candidates. Wondering why the management isn’t interested in listing on HK stock exchange.
06/9/2018
18:59
sportii: Everything else, other than the share price, appears positive. Big drop in share price on the other side of the pond, today. Is yesterdsy’s approval news not good enough for the big buyers? Disheartened sellers, perhaps.
Hutchison China Meditech share price data is direct from the London Stock Exchange
Your Recent History
LSE
HCM
Hutchison ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190524 15:02:03